Intravitreal anti-VEGF therapy for extrafoveal macular neovascularisation secondary to age-related macular degeneration: five-year results in a tertiary centre
Anti-VEGF therapy for extrafoveal MNV secondary to AMD stabilised or improved BCVA in approximately half of the patients; however, mean BCVA declined after five years. Long-term functional benefits were limited due to morphological changes in the macula, such as subfoveal atrophy.
Authors
- Faik Gelişken (ORCID: https://orcid.org/0009-0004-9418-4572)
- Nurullah Koçak (ORCID: https://orcid.org/0000-0001-8811-7294)
- D. Wénzel (ORCID: https://orcid.org/0000-0003-0714-3648)
- Caroline J. Gassel (ORCID: https://orcid.org/0000-0001-6718-7883)
- Kübra Atay Dinçer (ORCID: https://orcid.org/0000-0003-0349-2998)
Institutions
- Ondokuz Mayıs University (TR)
- Eskişehir Osmangazi University (TR)
- University of Tübingen (DE)
Publication Details
- Journal
- Eye
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1038/s41433-025-04057-w
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00